This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary CCR4 Therapeutic Antibody Development
Background of CCR4
BioVenic provides veterinary CCR4 therapeutic antibody development services covering the full workflow ranging from gene synthesis and animal immunization to antibody purification and characterization. CCR4 serves as a promising therapeutic target, particularly for the treatment of companion animal immune-mediated conditions including allergic disorders, autoimmune diseases, and certain cancers. Through our comprehensive one-stop services, we support the development of therapeutic antibodies capable of blocking the binding between CCR4 and its ligands, enabling further exploration of their therapeutic potential for diseased companion animals such as dogs and cats.
Background of CCR4
| Full Name | C-C motif chemokine receptor 4 |
|---|---|
| Aliases | CKR4, CD194, CMKBR4, ChemR13, CC-CKR-4, K5-5. |
| Target Profile | CCR4, belonging to the G protein-coupled receptor family, is widely expressed in immune cells such as T helper cells, natural killer cells, macrophages, dendritic cells, mast cells, and eosinophils. As a crucial chemokine receptor, CCR4 binds with its chemokine ligands to exert its functions, playing a significant role in diseases such as cancer and inflammation, and maintaining immune balance. |
MoA of CCR4
CCR4 activates a cascade of reactions with its associated G proteins and intracellular signaling molecules by binding with its specific ligands, CCL17 and CCL22. This process involves various signaling pathways, including PI3K, PKC, and MAPK, affecting processes such as chemotaxis, recruitment, and adhesion of cells. The migration of immune cells like Th2 cells and Treg cells is crucial in tissue inflammatory responses and immune surveillance. In the tumor microenvironment, CCR4 binding with CCL17/CCL22 induces a concentration of Treg cells around tumor cells, exerting an immunosuppressive effect and allowing tumors to evade the immune system's threats.
Fig.1 Schematic diagram of CCR4 signaling pathways, possible functions, cellular expression, and disease connections.1,2
Application in Veterinary Therapeutics
The CCL17-CCR4 axis is associated with regulatory T cell infiltration in canine prostate and bladder cancer tissues, and blocking CCR4 has shown potential clinical activity and increased survival rates without severe toxic reactions. These findings suggest that targeting CCR4 could be an effective strategy to reduce Treg-mediated immune suppression and enhance the immune response against tumors. Consequently, CCR4 antibodies may play a significant role in the treatment of canine cancers. In allergic diseases, CCR4 antibodies, by blocking the CCR4 receptor highly expressed on Th2 cells, selectively inhibit the migration of Th2 cells to inflamed tissues, showing potential in treating allergic diseases such as atopic dermatitis and asthma. Studies also indicate that abnormal expression of CCR4 is associated with the progression of autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.
Veterinary CCR4 Therapeutic Antibody Development Services
Considering the crucial role of CCR4 in canine and feline diseases, particularly allergic diseases, autoimmune disorders, and cancers, BioVenic offers veterinary CCR4 therapeutic antibody development services. We utilize various advanced antibody preparation technologies, including hybridoma cells, single B cells, and phage display techniques, to assist in developing therapeutic antibodies specifically targeting CCR4. Our services also include comprehensive antibody characterization, engineering, and species-specific antibody development to ensure the safety and efficacy of veterinary CCR4 therapeutic antibodies, enhancing the likelihood of achieving the desired therapeutic outcomes.
Please click the link below for more information about our veterinary CCR4 therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
BioVenic's one-stop service includes gene synthesis, animal immunization, antibody production, purification, and detailed characterization, optimized with professional support to enhance the efficiency and success rate of antibody development.
Our species-specific antibody development service meets the specific needs of different companion animals, adapting to the target species, reducing immunogenicity, and enhancing therapeutic effectiveness.
Our team employs novel technologies for high-quality veterinary therapeutic antibody development services, combined with stringent quality control processes to ensure the antibodies have high affinity and specificity.
Frequently Asked Questions
What three major categories of companion animal diseases can anti-CCR4 antibodies be applied to treat?
Anti-CCR4 therapeutic antibodies have research value for three types of pet disorders: allergic diseases such as canine atopic dermatitis and asthma, autoimmune diseases including rheumatoid arthritis, and malignant tumors like canine prostate and bladder cancer. Each disease relies on different mechanisms of the CCR4 signaling axis for intervention.
How does the CCR4-CCL17/CCL22 signaling axis drive inflammation and tumor immune escape in dogs and cats?
When CCR4 binds its ligands CCL17 and CCL22, it activates PI3K, MAPK and PLC-β downstream pathways, triggering chemotaxis and mass infiltration of Th2 inflammatory cells to inflamed tissues. In tumor microenvironments, this signal recruits immunosuppressive Treg cells around tumor lesions, helping tumor cells evade host immune surveillance.
What unique therapeutic effects do CCR4 blocking antibodies exert against pet tumors versus allergic inflammations?
For tumors: Antibodies block Treg recruitment, relieve local immune suppression, and restore the body's anti-tumor immune response to slow cancer progression. For allergies: They selectively block the migration of Th2 cells to lesion sites, cut off inflammatory cell aggregation, and alleviate pruritus, skin redness and respiratory allergic symptoms.
What full-process one-stop items are covered in your CCR4 antibody development pipeline for companion animals?
Our complete workflow includes target gene synthesis, customized animal immunization schemes, multi-platform antibody library screening, antibody purification, species-specific humanization modification (caninization/felinization), and full-spectrum functional characterization to verify receptor binding and pathway blocking activity.
What advantages does species transformation bring to CCR4 therapeutic antibodies for canine and feline clinical research?
We conduct CDR grafting, chimeric construction and fully canine/feline antibody transformation to minimize heterologous protein segments in antibody molecules. This drastically reduces the risk of immune rejection after administration to pets, extends antibody circulation half-life in vivo, and maintains high specific binding activity to the CCR4 receptor.
Partner with BioVenic
Targeting CCR4 in a range of companion animal diseases, including asthma, atopic dermatitis, and certain cancers, is gaining wide attention. BioVenic's comprehensive service for the development of veterinary CCR4 therapeutic antibodies assists in exploring the therapeutic potential of CCR4 blockade. If you have related needs, please do not hesitate to contact us immediately.
References
- Bogacka, Joanna, et al. "CC chemokine receptor 4 (CCR4) as a possible new target for therapy." International Journal of Molecular Sciences 23.24 (2022): 15638.
- Image retrieved from Figure 2 "CCR4—mechanisms of action, possible roles, cellular expression, and disease connections. "Bogacka, Joanna, et al., 2022, used under [CC BY 4.0], the image title was changed to "Schematic diagram of CCR4 signaling pathways, possible functions, cellular expression, and disease connections."